Autres langues Lyell Immunopharma, Inc.

Actions

LYEL

US55083R1041

Temps réel estimé Cboe BZX Autres places de cotation 20:37:07 16/07/2024			Varia. 5j.	Varia. 1 janv.
1,875 ^USD	+9,01 %		+16,56 %	-3,87 %

26/06	Lyell Immunopharma fait état d'une activité clinique dépendante de la dose dans le cadre de l'essai de phase 1 du Lyl797, un produit candidat à base de cellules CAR T ciblant Ror1 et amélioré par sa technologie exclusive d'anti-épuisement.	CI
06/05	Mise à jour sectorielle : Les actions du secteur de la santé en hausse en fin d'après-midi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lyell Immunopharma : Company Presentation	26/06
Lyell Immunopharma : Initial Clinical and Translational Data from Phase 1 Trial of LYL797, an Enhanced ROR1 targeted CAR T Cell Product Candidate	26/06
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology	26/06
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology	26/06
Lyell Immunopharma Reports Dose-Dependent Clinical Activity from Phase 1 Trial of Lyl797, A Ror1-Targeted Car-T Cell Product Candidate Enhanced with Its Proprietary Anti-Exhaustion Technology	26/06
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference	03/06
Lyell Immunopharma to Participate in BofA Securities Health Care Conference	07/05
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	06/05
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows	06/05
Lyell Immunopharma: Q1 Earnings Snapshot	06/05
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q1 Revenue $3,000	06/05
Lyell Immunopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024	06/05
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting	05/03
North American Morning Briefing : Stock Futures -2-	04/03
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q4 Revenue $13,000	28/02
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023	28/02
Lyell Immunopharma Announces Participation in March Investor Conferences	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lyell Immunopharma, Inc.

Actions

LYEL

US55083R1041

Autres langues

Filtres